The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Moderna Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
11 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Spikevax XBB.1.5 (andusomeran) has been approved for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
-
Australian Public Assessment Report (AusPAR)Spikevax (Elasomeran/davesomeran), a vaccine, has transitioned from provisional to full registration. Spikevax is for the prevention of coronavirus disease 2019 caused by SARS-CoV-2.
-
Australian Public Assessment Report (AusPAR)New AusPAR for Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2.
-
Australian Public Assessment Report (AusPAR)AusPAR for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) as booster dose for active immunisation to prevent COVID-19
-
Australian Public Assessment Report (AusPAR)AusPAR for SPIKEVAX COVID-19 VACCINE (elasomeran) as booster in 12 to 17 years of age for prevention of COVID-19
-
Australian Public Assessment Report (AusPAR)SPIKEVAX BIVALENT ORIGINAL/OMICRON - (elasomeran and imelasomer) for prevention of COVID-19
-
Australian Public Assessment Report (AusPAR)Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Elasomeran
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Elasomeran (mRNA-1273)
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Elasomeran